Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

Reichetzeder, Christoph and Websky, Karoline von and Tsuprykov, Oleg and Samarin, Azadeh Mohagheghi and Falke, Luise Gabriele and Putra, Sulistyo Emantoko Dwi and Hasan, Ahmed Abdallah and Antonenko, Viktoriia and Curato, Caterina and Rippmann, Jörg and Klein, Thomas and Hocher, Berthold (2017) Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. British Journal of Pharmacology, 174. pp. 2273-2286.

PDF Emantoko_Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors.pdf Download (6MB)

Abstract

BACKGROUND AND PURPOSE Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia–reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI. EXPERIMENTAL APPROACH IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin(1.5 mg·kg1 ·day1), vildagliptin (8 mg·kg1·day1) and sitagliptin (30 mg·kg1·day1). An additional group received sitagliptin until study end (before IRI: 30 mg·kg1·day1; after IRI: 15 mg·kg1·day1). KEY RESULTS Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group. CONCLUSIONS AND IMPLICATIONS In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage. Abbreviations AKI, acute kidney injury; CKD, chronic kidney disease; DPP4, dipeptidyl peptidase 4; ESRD, end-stage renal disease; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide type 1; IRI, ischaemia reperfusion injury; KC, keratinocyte chemoattractant; MCP-1, monocyte chemotactic protein 1; UniNX, uni-nephrectomy

Item Type:	Article
Subjects:	T Technology > T Technology (General)
Divisions:	Faculty of Technobiology > Department of Biology
Depositing User:	Ester Sri W. 196039
Date Deposited:	23 Mar 2021 09:07
Last Modified:	11 May 2021 03:11
URI:	http://repository.ubaya.ac.id/id/eprint/39068

Actions (login required)

View Item